BlinkLab Limited (ASX: BB1), a digital healthcare innovator developing AI-powered diagnostic tests for neurological conditions, participates in the landmark Monash Autism & ADHD Genetics and Neurodevelopment (MAGNET) study. The goal is to uncover novel data-driven subtypes using comprehensive deep phenotyping techniques and biomarkers, such as BlinkLab Dx 1. The study addresses the overlap between autism and ADHD, focusing on personalised diagnosis and treatment.
BlinkLab's prepulse inhibition (PPI) measure, a proxy for sensorimotor gating, will help differentiate autism and ADHD characteristics within the cohort. The inclusion of undiagnosed family members also explores familial risk factors. BlinkLab CEO Dr. Henk-Jan Boele emphasises the potential of digital biomarkers to revolutionise psychiatric diagnostics, while Monash University’s Professor Mark Bellgrove highlights the collaboration’s significance in advancing outcomes for children and families.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
